Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata - National Alopecia Areata Foundation | NAAF

Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata

Study type: Clinical Trials Posting date: 09/17/2025 Last updated: 09/17/2025 Status: Active Phase: Phase 3 Eligibility:

Clinical presentation compatible with alopecia areata with a current episode lasting at least 6 months and not exceeding 10 years; between 12 to <18 years of age; at least 50% scalp hair loss; willing to comply with the study visits and requirements of the study protocol
Drug: deuruxolitinib (Leqselvi) Administration: oral Sponsor: Sun Pharma ClinicalTrials.gov link: Click here Location: Multiple locations in USA and Canada


 Description:
This study evaluates the safety and effectiveness of deuruxolitinib (Leqselvi) in adolescents aged 12 to less than 18 years who have 50% or greater scalp hair loss, beginning with a double-blind, randomized, placebo-controlled Treatment Period of 24 weeks. Subjects 12 to <18 years of age having at least 50% hair loss as measured by SALT and meeting eligibility criteria will be randomized to deuruxolitinib or placebo treatment. In the Open-label Extension part of the study, participants from the Treatment Period will receive deuruxolitinib for 52 weeks.
For more information, including trial site locations, view the trial listing on Clinicaltrials.gov.